Bioarray Genetics is Drug Discovery in United States that focus on machine learning algorithms business. Founded in 2011. They cover business area such as developer, predictive test, order, cancer treatment decision, patient quality, life, survival outcome, gene, minimal overlap, unique RNA biomarker, phenotypic signature, machine learn algorithm, clinician, information, analytical tool, companion diagnostic, oncology drug.
2011
( 13 years old in 2024 )
Machine Learning Algorithms
-
400 Farmington Avenue
Farmington, CT 06032
United States
Private
developerpredictive testordercancer treatment decisionpatient qualitylifesurvival outcomegeneminimal overlapunique RNA biomarkerphenotypic signaturemachine learn algorithmclinicianinformationanalytical toolcompanion diagnosticoncology drug
* We use standard office opening hours in near Bioarray Genetics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Bioarray Genetics is Drug Discovery business from United States that founded in 2011 (13 years old in 2024), Bioarray Genetics business is focusing on Machine Learning Algorithms.
Bioarray Genetics headquarter office and corporate office address is located in 400 Farmington Avenue Farmington, CT 06032 United States.
Bioarray Genetics was founded in United States.
In 2024, Bioarray Genetics is currently focus on machine learning algorithms sector.
Above is snippet of Google Trends for "machine learning algorithms" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Bioarray Genetics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
